Comparative Pharmacology
Head-to-head clinical analysis: NORPACE versus NORPACE CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORPACE versus NORPACE CR.
NORPACE vs NORPACE CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ic antiarrhythmic agent; blocks voltage-gated sodium channels, slowing conduction velocity and prolonging refractory periods in cardiac tissue.
Class Ia antiarrhythmic agent; decreases myocardial excitability and conduction velocity, and prolongs refractory period by blocking sodium channels.
150 mg orally every 6 hours (maximum 300 mg per dose), extended-release formulation 300 mg every 12 hours.
Disopyramide controlled-release: 200 mg orally every 12 hours; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged in renal impairment (up to 24 hours).
Terminal elimination half-life: 6-12 hours (normal renal function); prolonged to 12-20 hours in renal impairment. In coronary artery disease, half-life may be extended due to reduced clearance.
Renal: 40-60% unchanged; biliary/fecal: minor (10-20%).
Renal (50-57% unchanged), hepatic metabolism (30-40%), fecal (<10%). Dose adjustment required for CrCl <40 mL/min.
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)